文献速递预防保健、筛查与疫苗慢病管理

男性口咽癌结局的种族差异与HPV状态

More than cervical cancer: Understanding racial/ethnic disparities in oropharyngeal cancer outcomes among males by HPV status.
PubMed 文献 · Ann Fam Med · 2022-04-01

研究基于北美癌症登记数据,分析2005至2016年175843例男性口咽癌患者,发现92.2%为HPV相关且83.6%为白人,白人晚期HPV相关口咽癌年龄调整发病率增长超50%。黑人HPV相关口咽癌平均生存期低于白人,且调整治疗因素后黑人癌症特异性死亡风险仍升高,而西班牙裔的升高消失。

要点

  • 男性口咽癌绝大多数为HPV相关(92.2%),白人占83.6%。
  • 白人与黑人晚期诊断无差异,但医疗补助或无保险者晚期风险更高。
  • 黑人HPV相关口咽癌平均生存期及调整累积生存率最低。

核心结论

  • 为降低晚期口咽癌发病率,应倡导HPV疫苗接种及可能的HPV口咽癌筛查,尤其针对白人男性。
  • 黑人男性口咽癌死亡风险升高,需进一步研究生物学机制、行为或合并症因素。

研究设计与样本

  • 全国性基于人群的回顾性队列研究,使用北美中央癌症登记协会Cancer in North America Deluxe数据集,覆盖93%美国人口。

主要发现

  • 大多数男性口咽癌为HPV相关(92.2%),白人占83.6%。
  • 2005至2016年白人晚期HPV相关口咽癌年龄调整发病率增长超过50%。
  • 白人与黑人(aOR 0.99,95%CI 0.94-1.05)或西班牙裔(aOR 0.96,95%CI 0.89-1.03)的晚期诊断无差异,其他种族晚期诊断几率低15%(95%CI 0.79-0.95)。
  • HPV相关口咽癌中,黑人平均生存69.72个月(95%CI 68.14-71.31),西班牙裔91.89个月(95%CI 89.87-93.91),均低于白人99.63个月(95%CI 99.18-100.07),p<0.01。
  • 黑人(aHR 1.78,95%CI 1.70-1.87)、西班牙裔(aHR 1.11,95%CI 1.03-1.19)及HPV相关口咽癌(aHR 1.25,95%CI 1.17-1.34)癌症特异性死亡风险更高。

关键数值与推荐

  • 晚期疾病的独立预测因素包括医疗补助(aOR 1.37,95%CI 1.28-1.46)、无保险(aOR 1.44,95%CI 1.32-1.57)及HPV相关口咽癌(aOR 3.53,95%CI 3.37-3.70)。
  • 黑人HPV及非HPV相关口咽癌的调整累积生存率最低(p<0.001)。
  • 调整治疗因素后,西班牙裔的较高死亡风险消失,但黑人仍存在。

临床怎么用

  • 在全科实践中应关注男性HPV疫苗接种,尤其白人男性,以预防口咽癌。
  • 对医疗补助或无保险男性患者,需警惕口咽癌晚期诊断风险。
  • 黑人男性口咽癌患者预后较差,应加强随访和综合管理。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Context: Over the last two decades the incidence of male oropharyngeal cancers (OPCa) has increased rapidly in the United States, yet OPCa is mostly preventable. Differences in OPCa incidence and outcomes by race/ethnicity and human papillomavirus (HPV) status have not been previously studied. Objective: Examine racial/ethnic disparities in HPV-related and non-HPV related OPCa outcomes among males. Study Design: Nationwide population-based retrospective cohort study. Setting or Dataset: North American Association of Central Cancer Registries' Cancer in North America Deluxe dataset, covering 93% of the U.S. population. Population studied: Males diagnosed with OPCa in the U.S. between January 2005 and December 2016 (N=175,843). Outcome Measures: OPCa incidence rates by race/ethnicity [Non-Hispanic White, Non-Hispanic Black, Hispanic, Non-Hispanic Other] and HPV status (HPV-related or non-HPV-related); late-stage diagnosis; mean and cumulative survival; cancer-specific mortality. Results: Most male OPCa were HPV-related (92.2%) and in Whites (83.6%), with over 50% increase from 2005 to 2016 in age-adjusted incidence of late-stage HPV-related OPCa among Whites. There was no difference in late-stage diagnosis between Whites and Blacks (aOR, 0.99, 95% CI, 0.94-1.05) or Hispanics (aOR, 0.96, 95% CI, 0.89-1.03), while Other race had 15% lower odds of late-stage diagnosis (95% CI, 0.79-0.95). Independent predictors of late-stage disease included having Medicaid (aOR, 1.37, 95% CI, 1.28-1.46) or no insurance (aOR, 1.44, 95% CI, 1.32-1.57) and HPV-related OPCa (aOR, 3.53, 95% CI, 3.37-3.70). Lower mean survival in HPV-related OPCa compared with Whites (99.63 months, 95% CI, 99.18-100.07) was seen among Blacks (69.72 months, 95% CI, 68.14-71.31) and Hispanics (91.89 months, 95% CI, 89.87-93.91; p < 0.01). Blacks had lowest adjusted cumulative survival for HPV and non-HPV related OPCa (p<0.001). Blacks (aHR, 1.78, 95% CI, 1.70-1.87), Hispanics (aHR, 1.11, 95% CI, 1.03-1.19), and HPV-related OPCa (aHR, 1.25, 95% CI, 1.17-1.34) had higher cancer-specific mortality. Adjusting for treatment eliminated the higher mortality among Hispanics, but not in Blacks. Conclusions: To decrease incidence rates of late stage OPCa, HPV vaccination and possibly, HPV OPCa screening should be advocated, especially in White males. Further research to explicate possible biologic mechanisms and behaviors or comorbidities contributing to the higher OPCa mortality among Black males is needed.

来源:Ann Fam Med,查看原文。版权归原作者所有。

引用

  1. Villalona S, Ferrante J, Villalona S, et al. More than cervical cancer: Understanding racial/ethnic disparities in oropharyngeal cancer outcomes among males by HPV status. Ann Fam Med. 2022. PMID: 36696662. doi:10.1370/afm.20.s1.2625

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。